Table 1.
Demographics and Classification of Patients With Acute Myeloid Leukemia
| Characteristic | All Patients (N = 144) |
IFI (n = 25) |
No IFI (n = 119) |
|---|---|---|---|
| Age, y, median (IQR) | 72 (66–76) | 73 (65–78) | 72 (66–76) |
| Sex, female | 71 (49) | 10 (40) | 61 (51) |
| Death | 38 (26) | 10 (40.0) | 28 (23.5) |
| AML classification | |||
| Secondary AML | 59 (41) | 13 (52) | 46 (39) |
| De novo AML | 35 (24) | 7 (28) | 28 (24) |
| ELN classification | |||
| Unknown/unable to assess | 5 (3.5) | 1 (4) | 4 (3.4) |
| Unfavorable | 92 (64) | 18 (72) | 74 (62) |
| Intermediate | 23 (16) | 2 (8) | 21 (18) |
| Favorable | 24 (17) | 4 (16) | 20 (17) |
| VEN/AZA duration, d, median (IQR) | 137 (56–268) | 206 (62–292) | 133 (55–256) |
| Duration of neutropenia, d, median (IQR) | 35 (19–58) | 55 (38–68) | 32 (14–55) |
| Antifungal prophylaxisa | 10 (6.9) | 0 (0) | 10 (8.4) |
| Anidulafungin | 6 (60) | 0 (0) | 6 (60) |
| Azole | 5 (50) | 0 (0) | 5 (50) |
| Fluconazole | 4 (80) | 0 (0) | 4 (80) |
| Isavuconazole | 1 (20) | 0 (0) | 1 (20) |
| Antifungal prophylaxis duration, d, median (IQR) | 31 (9–63) | NA | 31 (9–63) |
Data are presented as No. (%) of patients unless otherwise indicated.
Abbreviations: AML, acute myeloid leukemia; ELN, European LeukemiaNet; IFI, invasive fungal infection; IQR, interquartile range; NA, not assessed; VEN-AZA, venetoclax/azacitidine.
a
May have received >1 antifungal agent.